The biotechnology sector is advancing rapidly, fueled by significant venture capital investments that are enabling companies to achieve major breakthroughs.
To stay informed about the latest funding activities and discover more biotech companies making waves, follow the live feed of deals on VentureRadar using this link. Below, we highlight a selection of biotech companies that have secured funding in the past two weeks, showcasing the diversity and innovation across the sector.
Seaport Therapeutics Closes $225M Series B Financing Round
Seaport Therapeutics, based in the USA, has secured $225 million in a Series B financing round. The company specializes in developing novel neuropsychiatric medications using its proprietary Glyph™ technology. Their focus is on enhancing oral bioavailability and minimizing liver-related side effects to improve treatments for individuals with neuropsychiatric disorders.
Kiwi Rapid Diagnostics Startup DNAiTECH Raises NZ$1 Million Pre-Seed Round
New Zealand’s DNAiTECH has raised NZ$1 million in a pre-seed funding round. The company develops instant, lab-free diagnostic tests utilizing advanced Loop-mediated isothermal amplification (LAMP) technology. Their handheld device integrates with smartphones to rapidly identify animal and human diseases at the point of care, delivering results within minutes.
Superluminal Medicines Nets $120M Series A
Superluminal Medicines, a U.S.-based company, has secured $120 million in a Series A funding round. They develop medicines using generative biology, chemistry, and machine learning to enhance the speed and accuracy of drug discovery. Their innovative platform models protein shapes to design highly selective compounds targeting precise structural changes for therapeutic effects.
Terray Therapeutics Closes $120M Series B Funding Round
Terray Therapeutics, located in the USA, has closed a $120 million Series B funding round. The company integrates generative AI, high-throughput experimentation, medicinal chemistry, and nanotechnology to develop innovative small molecule therapeutics. Their unique platform accelerates drug development, addressing challenging therapeutic targets to enhance human health.
eGenesis Bags $191 Million Series D
eGenesis, a U.S.-based life sciences company, has raised $191 million in a Series D funding round. They focus on developing human-compatible engineered organs using CRISPR technology. By advancing product candidates for transplant applications and scaling production capacities, eGenesis aims to address the global shortage of transplantable organs.
Nuclera Closes $75 Million USD Financing
Nuclera, from the United Kingdom, has closed a $75 million USD financing round. The company offers a benchtop protein system that accelerates expression and purification workflows by automating construct screening and enabling rapid protein scale-up. Their proprietary enzyme-mediated DNA synthesis platform aims to produce highly accurate, ultra-long DNA products efficiently.
Antiverse Raises £3.5M to Advance GenAI Antibody Design Platform
Antiverse, a UK-based company, has raised £3.5 million to enhance its GenAI antibody design platform. They specialize in designing antibodies for challenging targets using machine learning, which enhances predictive accuracy and accelerates discovery. Their in silico models aim to streamline antibody development for essential therapies and biotech collaborations.
Sunbird Bio Raises Additional $14M in Funding
Sunbird Bio, based in the USA, has raised an additional $14 million in funding. The company develops advanced proprietary blood-based diagnostic platforms to detect and monitor disease-specific proteins accurately. Their enVision platform enables early diagnosis of neurological disorders by providing rapid and versatile disease detection.
Mid-Atlantic BioTherapeutics Launches $5 Million Funding Round
Mid-Atlantic BioTherapeutics, a U.S. clinical-stage biotechnology company, has launched a $5 million funding round under Regulation D 506(c). They develop novel immunotherapies for infectious diseases and central nervous system disorders using innovative platforms like IMT504 and USP30-targeted technologies. The company’s work aims to combat life-threatening infections and treat conditions such as Parkinson’s and Alzheimer’s diseases.
Tolerance Bio Raises $17.2M in Seed Financing
Tolerance Bio, a U.S.-based company, has raised $17.2 million in seed financing. They develop allogeneic, iPSC-based cell therapy platforms and pharmacological thymus therapies to address immune-mediated diseases. By focusing on preserving and restoring thymus function—the master regulator of immune tolerance—they aim to effectively control immune tolerance and improve health span.
Monument Therapeutics Secures £1M Investment for Schizophrenia Programme
Monument Therapeutics, from the UK, has secured a £1 million investment to fund its schizophrenia program and drive growth. The company develops innovative treatments for the cognitive symptoms of schizophrenia, utilizing digital assessments to match patients with specialized pharmaceutical therapies. Their precision medicine approach uses proprietary digital biomarkers to identify patients with homogeneous neurobiology.
Shift Bioscience Raises $16M in Seed Funding
Shift Bioscience, a UK-based company, has raised $16 million in seed funding. They develop advanced AI-driven cell simulation platforms to predict, identify, and validate gene sets for safely rejuvenating cells and combating age-related diseases. Their lead candidate, SB200, aims to reverse mitochondrial dysfunction, targeting rare mitochondrial diseases and exploring applications in age-related conditions.
InvIOs Raises €8.2M in Series A Funding
InvIOs, an Austrian biotechnology company, has raised €8.2 million in Series A funding. They focus on developing novel cancer therapies by leveraging immune system activation to create personalized, targeted treatments for solid tumors. Utilizing advanced small molecule and cell therapy approaches, their pipeline includes autologous cell therapies targeting the novel master checkpoint inhibitor Cbl-b.
MiLaboratories Gets $10M to Accelerate Genomic Research
MiLaboratories, based in the USA, has raised $10 million to enhance its platform for genomic data analysis. The company develops innovative tools aiming to simplify genomic data analysis for biologists. Their computational biology platform features data visualization and generative AI, serving as a marketplace for specialized computational tools to support commercial efforts in bioinformatics.
Booster Therapeutics Raises $15M in Seed Financing
Booster Therapeutics, a German company, has raised $15 million in seed financing. They are developing a new class of proteasome activator medicines to treat complex indications, focusing on neurodegenerative diseases like Parkinson’s and Alzheimer’s. Their approach addresses the collapse of cellular homeostasis, a key feature of aging, aiming to restore cellular function.
Cartherics’ AU$15M Series B Advances CTH-401 for Ovarian Cancer
Cartherics, an Australian company, has raised AU$15 million in a Series B funding round to advance CTH-401 for ovarian cancer. They develop chimeric antigen receptor natural killer (CAR-NK) therapies for diseases such as ovarian cancer. By combining gene editing and CAR technology, Cartherics aims to provide diverse off-the-shelf treatments for patients.
LUMICKS Receives €20M from European Investment Bank to Accelerate Cancer Drug Discovery
Amsterdam-based LUMICKS has secured €20 million from the European Investment Bank to accelerate drug discovery for cancer. The company provides innovative life science tools and technology to improve cellular understanding and accelerate research. Their platforms empower researchers through Dynamic Single-Molecule and Cell Avidity analysis, offering unparalleled insights into biological processes.
Cytovale Completes $100 Million Series D Funding
CytoVale, a U.S. medical technology company, has completed a $100 million Series D funding round. They specialize in rapid sepsis diagnostic solutions through IntelliSep, a U.S. FDA-cleared cellular host diagnostic. By leveraging cell mechanics and machine learning, CytoVale aims to revolutionize diagnostics and improve patient outcomes in sepsis care.
Clock.bio Raises $5.3M in Seed Funding
Clock.bio, a UK-based biotech company, has raised $5.3 million in seed funding. They focus on developing novel treatments for age-related diseases by decoding rejuvenation programs in human cells. Utilizing genome-wide CRISPR screening and single-cell RNA sequencing, they aim to understand and manipulate the genes regulating cellular rejuvenation for clinical applications.
Amprion Announces $6M Series B Financing
Amprion, based in the USA, has secured $6 million in a Series B financing round. The company advances the diagnosis of neurodegenerative disorders, aiming to revolutionize brain disease diagnosis. By improving detection methods for conditions like Alzheimer’s and Parkinson’s diseases, Amprion seeks to enhance early diagnosis and patient outcomes.
Babson Diagnostics Receives Strategic Investment from BD
U.S.-based Babson Diagnostics has received a strategic investment from Becton, Dickinson and Company (BD). The company offers innovative diagnostic blood testing solutions, aiming to make blood testing more convenient and accessible. Their proprietary technology produces accurate results from small capillary samples collected at retail locations, analyzed at their CLIA-certified clinical laboratory.
Basecamp Research Raises $60M to Enhance AI Understanding of Biology
Basecamp Research, a UK company, has raised $60 million to develop advanced biological systems and fill AI data gaps. Utilizing a vast biological database, they enhance AI’s understanding of biology to design comprehensive biological systems with superior control and performance. Basecamp collaborates with biopharma companies to push the boundaries of known biology.
Holobiome Closes Oversubscribed Seed Round
Holobiome, a U.S.-based biotechnology startup, has closed an oversubscribed seed round. The company develops comprehensive collections of human gut bacteria to map how the microbiome influences health. Focusing initially on the gut-brain axis, their lead program targets biology relevant to depression, aiming to develop novel consumer products and drugs.
Purespring Therapeutics Raises $105M to Advance Gene Therapy
Purespring Therapeutics, from the UK, has raised $105 million to bring its gene therapy programs into clinical trials. The company develops gene therapies targeting specialized renal cells to treat kidney diseases. By addressing both rare monogenic and common forms of kidney disease, they aim to halt disease progression and improve patient outcomes.
Somagenetix Raises CHF10M in Series A Financing
Somagenetix, a Swiss biotechnology company, has raised CHF10 million in Series A financing. They focus on developing innovative gene therapies for phagocyte disorders, particularly Chronic Granulomatous Disease. Leveraging advanced biotechnological methods, Somagenetix aims to address the underlying genetic causes and provide effective treatments for this rare genetic disorder.
Arda Therapeutics Raises $43M in Series A Financing
Arda Therapeutics, based in the USA, has secured $43 million in Series A funding. The company develops targeted cell depletion therapies for chronic diseases, aiming to improve treatment efficacy and reduce dosing frequency. Their platform is applicable across various diseases, including fibrotic conditions like pulmonary fibrosis, autoimmune, and metabolic disorders.
City Therapeutics Launches with $135 Million Series A Financing
U.S.-based City Therapeutics has launched with $135 million in Series A financing to lead the future of RNAi-based medicine. They develop next-generation engineered siRNAs to enhance and expand the effectiveness of RNA interference therapies across multiple therapeutic areas. Their platform designs novel RNAi triggers and targeting ligands for specific delivery.
Arda Therapeutics Secures $43M Series A with Backing from Eli Lilly and a16z
Arda Therapeutics, a U.S. company, has raised $43 million in Series A financing, backed by Eli Lilly and Andreessen Horowitz (a16z). They focus on combating chronic diseases and aging by targeting and eliminating specific pathogenic cells responsible for these conditions. Using single-cell data, they design therapies to eliminate pathogenic cells and improve health span.
MARAbio Raises $19 Million to Develop Autism Diagnostic Blood Test
MARAbio, based in the USA, has raised $19 million in an initial Series A round led by MAK Capital. The company has developed a proprietary blood test and therapeutic interventions for the early detection and prevention of Maternal Autoantibody Related Autism (MARA) in children. Their test predicts the likelihood of MARA with over 90% accuracy, enabling early intervention and tailored care strategies.
Orasis Pharmaceuticals Closes $78M Financing
Orasis, an Israeli pharmaceutical company, has closed a $78 million financing round. They develop products for eye conditions, notably Qlosi™, an innovative eye drop for presbyopia. With expertise in research, finance, and business development, Orasis aims to improve quality of life for people affected by presbyopia worldwide.
Generare Raises €5M in Seed Funding
Generare, a France-based biotech company, has raised €5 million in seed funding. They offer a data-driven discovery platform for uncovering untapped bioactive molecules using novel cloning techniques. By utilizing synthetic biology, DNA sequencing, and computational biology, Generare accelerates the identification of Natural Products from soil bacteria.
Rege Nephro Completes Series B Funding to Accelerate Kidney Disease Therapy Trials
Rege Nephro, a Japanese company, has completed a Series B funding round to accelerate trials for kidney disease therapies. They develop therapeutics and cell therapies for kidney, liver, and pancreas diseases using iPSC-based technology. Focusing on chronic kidney disease, they aim to treat patients with cell therapy derived from nephron progenitor cells.
Judo Bio Raises $100M in Seed and Series A Financing
Judo Bio, a U.S.-based biotechnology company, has raised $100 million across seed and Series A financing rounds. They develop oligonucleotide medicines for renal diseases using their proprietary gene silencing platform, STRIKE. This platform creates ligand-RNA conjugate drugs for receptor-mediated uptake by specific kidney cell types, targeting disease-modifying genes.
These recent funding rounds highlight the dynamic and multifaceted nature of innovation within the biotechnology sector, spanning areas such as oncology, metabolic health, rapid diagnostics, and enzyme engineering. Follow the live feed of biotech deals on VentureRadar to keep up to date with all the latest rounds.
Subscribe for alerts on new companies featured on Startups.Bio
View all recently featured startups